ReviewCurrent issues in molecular biology2026
Proteinase-Activated Receptor 2 (PAR2) Deficiency and Cardiovascular Regulation: Context-Dependent Effects on Inflammation and Fibrosis.
Review in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PAR2 Regulates Cardiac Pressure and Vascular Function Through Context-Dependent Signalling Mechanisms.Current issues in molecular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Proteinase-activated receptor 2 is a G protein-coupled receptor that regulates vascular tone and inflammatory signalling in the circulatory system. The roles of PAR2 appear complex and sometimes opposing. Studies using PAR2-deficient mice provide a framework to define these effects at the system level. This review examines cardiovascular phenotypes associated with PAR2 deficiency in basal conditions and in disease. PAR2 deficiency produces modest increases in arterial blood pressure and vascular stiffness while preserving endothelial vasodilator function. Cardiac function remains largely normal in young PAR2-deficient animals but changes with age. Older PAR2-deficient mice develop diastolic dysfunction and cardiac fibrosis. In disease models, PAR2 deficiency has been associated with increased fibrosis in cardiac and vascular tissues and reduced vascular inflammation in atherosclerosis. PAR2 deficiency is also associated with reduced plaque progression and features of plaque stabilisation. In myocardial ischaemia models, PAR2 deficiency has been associated with reduced cardiac injury and adverse remodelling. The effects of PAR2 deficiency on inflammatory signalling vary according to tissue and disease context. Together, these findings suggest that the cardiovascular consequences of PAR2 deficiency depend on physiological and pathological context. Future studies should define cell-specific mechanisms to guide therapeutic targeting of PAR2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.